ConductScience.org, home

Paper25730813

Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus.

Azeem S and 4 others. Pak J Pharm Sci, 2015. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. Papers, record 25730813. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25730813

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus.
PubMed
Journal
Pak J Pharm Sci
PubMed
Year
2015
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
0.94
iCite
Revised in PubMed
2015-03-03
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Azeem SSidra
2Ashraf MMuhammad
3Rasheed MAMuhammad Adil
4Anjum AAAftab Ahmad
5Hameed RRabia

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
IvermectinMajor topic
Newcastle disease virusMajor topic
Animals
Cell Line
Cell Survival
Chick Embryo
Ribavirin

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04551755Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19BackgroundClinicalTrials.gov
NCT04602507Ivermectin in Adults With Severe COVID-19.BackgroundClinicalTrials.gov

Download CSV of trials

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
42317461Ivermectin in veterinary medicine: a narrative review of antiparasitic efficacy, resistance evolution, antiviral evidence, and One Health implications.Front Vet Sci2026https://conductscience.org/library/papers/42317461PubMed
41874838Molecular characterization of virulent genotype XIII Newcastle disease virus isolates from desi-chickens in Namakkal, South India.Vet Res Commun2026https://conductscience.org/library/papers/41874838PubMed
40006532
Experimental Investigation into the Design, Optimization, Toxicity, and Anti-Viral Efficacy of Proliposomes Loaded with Ivermectin Against Infectious Bronchitis Virus Using an Embryonated Chicken Egg Model.
Pharmaceutics2025https://conductscience.org/library/papers/40006532PubMed
37422646Patch-clamp studies and cell viability assays suggest a distinct site for viroporin inhibitors on the E protein of SARS-CoV-2.Virol J2023https://conductscience.org/library/papers/37422646PubMed
35855004The Politicization of Ivermectin Tweets During the COVID-19 Pandemic.Open Forum Infect Dis2022https://conductscience.org/library/papers/35855004PubMed
35382155Evaluation of ivermectin antiviral activity against avian infectious bronchitis virus using a chicken embryo model.Int J Vet Sci Med2022https://conductscience.org/library/papers/35382155PubMed
35359702Can anti-parasitic drugs help control COVID-19?Future Virol2022https://conductscience.org/library/papers/35359702PubMed
34722735Regression of bovine cutaneous papillomas via ivermectin-induced immunostimulant and oxidative stress.J Adv Vet Anim Res2021https://conductscience.org/library/papers/34722735PubMed
34163159Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.Int J Nanomedicine2021https://conductscience.org/library/papers/34163159PubMed
33713753Ivermectin also inhibits the replication of bovine respiratory viruses (BRSV, BPIV-3, BoHV-1, BCoV and BVDV) in vitro.Virus Res2021https://conductscience.org/library/papers/33713753PubMed
33614709Therapeutic Strategies in the Management of COVID-19.Front Mol Biosci2020https://conductscience.org/library/papers/33614709PubMed
33427370A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.Fundam Clin Pharmacol2021https://conductscience.org/library/papers/33427370PubMed
32837982Known drugs and small molecules in the battle for COVID-19 treatment.Genes Dis2020https://conductscience.org/library/papers/32837982PubMed
32824399Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects.Pharmaceuticals (Basel)2020https://conductscience.org/library/papers/32824399PubMed
32752944Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2.J Biomol Struct Dyn2021https://conductscience.org/library/papers/32752944PubMed
32533071Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.J Antibiot (Tokyo)2020https://conductscience.org/library/papers/32533071PubMed
32473642Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.Ann Clin Microbiol Antimicrob2020https://conductscience.org/library/papers/32473642PubMed
32322397Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.New Microbes New Infect2020https://conductscience.org/library/papers/32322397PubMed
28799438Structural evaluation of the peritubular sheath of rat's testes after administration of ribavirin: A possible impact on the testicular function.Int J Immunopathol Pharmacol2017https://conductscience.org/library/papers/28799438PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25730813

GET https://conductscience.org/api/papers/v1/25730813/authors